Use of Polyphenols in the Treatment of Cancer
The present invention relates to polyphenol compounds, compositions thereof, and methods for treating or preventing cancer in a subject, the methods comprising co-administering to a subject an effective amount of two or more polyphenol compounds or a polyphenol composition thereof.
1 . A method for treating cancer in a subject in need thereof comprising,
co-administering to said subject a therapeutically effective amount of pterostilbene and quercetin,
wherein said cancer is characterized by overexpression or constitutive activation of NF-κB or Bcl-2.
2 . The method of claim 1 , wherein said treatment has a cytostatic effect on said cancer.
3 . The method of claim 1 , wherein said treatment has a cytotoxic effect on said cancer.
4 . The method of claim 3 , wherein said treatment further comprises administering an additional therapeutic agent.
5 . The method of claim 4 , wherein said additional therapeutic agent is a polyphenol.
6 . The method of claim 5 , wherein said polyphenol is resveratrol.
7 . The method of claim 5 , wherein said additional polyphenol is selected from the group consisting of: TMS, 3,4′,4-DH-5-MS, 3,5-DH-4′MS, catechin, caffeic, hydroxytyrosol, rutin, and quercitrin.
8 . The method of claim 1 , wherein said cancer is selected from the group consisting of skin cancer, colon cancer, advanced colorectal cancer, breast cancer, prostate cancer, lung cancer, uveal melanoma, brain cancer, lung cancer, bone cancer, pancreas cancer, fibrosarcoma and rhabdomyosarcoma.
9 . The method of claim 1 , wherein said cancer is colon cancer or advanced colorectal cancer.
10 . The method of claim 1 further comprising treating said subject with chemotherapy or a radiation therapy.
11 . The method of claim 1 further comprising treating said subject with chemotherapy and a radiation therapy.
12 . The method of claim 11 , wherein said treatment causes regression of said cancer.
13 . The method of claim 10 , wherein said treatment has no systemic toxicity in said subject.
14 . The method of claim 10 , wherein said chemotherapy uses an agent selected from the group consisting of: oxaliplatin, fluorouracil, leucovorin, 5-fluorouracil, leucovorin, and irinotecan.
15 . The method of claim 10 , wherein said chemotherapy is an irinotecan-based chemotherapy or an oxaliplatin-based chemotherapy.
16 . The method of claim 15 , wherein said chemotherapy comprises administering to said subject a combination of oxaliplatin, fluorouracil and leucovorin, or a combination of 5-fluorouracil, leucovorin, and irinotecan.
17 . The method of claim 1 , wherein said pterostilbene and quercetin are administered orally.
18 . The method of claim 1 , wherein said pterostilbene and quercetin are administered intravenously.
19 . A method for treating colorectal cancer in a subject in need thereof comprising,
co-administering to said subject a therapeutically effective amount of pterostilbene and quercetin,
wherein said treatment inhibits cancer cell growth or kills cancer cells.
20 . The method of claim 19 further comprising treating said subject with a radiation therapy or a chemotherapy.
21 . The method of claim 19 , further comprising treating said subject with a radiation therapy and a chemotherapy.
22 . The method of claim 20 , wherein said chemotherapy is an irinotecan-based chemotherapy or an oxaliplatin-based chemotherapy.
23 . The method of claim 22 , wherein said chemotherapy comprises administering to said subject a combination of oxaliplatin, fluorouracil and leucovorin, or a combination of 5-fluorouracil, leucovorin, and irinotecan.
24 . The method of claim 20 , wherein said treatment causes regression of said cancer in said subject.
25 . A method for treating colorectal cancer in a subject comprising,
co-administering to said subject a therapeutically effective amount of pterostilbene and quercetin in combination with a chemotherapy or a radiation therapy.
26 . A method for treating colorectal cancer in a subject in need thereof comprising,
co-administering to said subject a therapeutically effective amount of pterostilbene and quercetin in combination with a chemotherapy and a radiation therapy
wherein said treatment causes regression of said cancer.
27 . The method of claim 25 , wherein said chemotherapy comprises administering to said subject a combination of oxaliplatin, fluorouracil and leucovorin, or a combination of 5-fluorouracil, leucovorin, and irinotecan.
28 . The method of claim 25 , wherein said pterostilbene and quercetin are administered intravenously.
29 . The method of claim 25 , wherein said treatment has no systemic toxicity to said subject.
30 . The method of claim 1 , 19 , 25 or 26 , wherein said subject is a human.
31 . The method of claim 1 , 19 , 25 or 26 , wherein said treatment delivers a dose of quercetin of 800 mg/m 2 and a dose of pterostilbene of 800 mg/m 2 to said subject.
32 . The method of claim 1 , wherein said pterostilbene and quercetin are administered concurrently.
33 . The method of claim 1 , wherein said pterostilbene and quercetin are administered sequentially.